Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

NCT01740557 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma
Stage III Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions

BIOLOGICAL: Aldesleukin
BIOLOGICAL: CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes
DRUG: Cyclophosphamide
DRUG: Fludarabine Phosphate
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: NGFR-transduced Autologous T Lymphocytes
OTHER: Quality-of-Life Assessment

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]